Latest Healthcare It News

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

Mach7 Technologies reports a modest rise in recurring revenue alongside a comprehensive commercial transformation, positioning itself for growth in AI-driven medical imaging.

Mach7 Technologies has initiated Phase 1 of the Veterans Health Administration’s National Teleradiology Program, deploying its core imaging software across 125 sites. This milestone sets the stage for a potential $11.7 million contract and broader expansion within the VHA network.

Visionflex Group has converted $3.25 million of debt into equity at a 100% premium, emerging debt-free and poised for growth. The company’s Q1 FY26 results show a 34% increase in annual recurring revenue, supported by new product launches targeting the expanding virtual healthcare market.

IMEXHS Limited reported a 9% rise in Q3 FY25 revenue and a positive swing to $0.6m underlying EBITDA, reaffirming full-year guidance. Key contract wins and AI-driven efficiencies underpin margin gains despite political uncertainties in Colombia.

Robex Resources reports strong Q3 2025 progress with Kiniero Gold Project on track for Q4 first gold pour, raises C$148 million via accelerated warrant exercise, and announces merger plans with Predictive Discovery.

Resmed Inc. kicked off fiscal 2026 with robust 9% revenue growth and a notable 290 basis points gross margin expansion, signaling strong momentum in home healthcare innovation. The company also declared a $0.60 dividend and executed a $150 million share buyback, underscoring confidence in its strategic direction.

Echo IQ Limited has advanced its EchoSolv heart failure solution towards FDA submission, driven by a landmark clinical validation study and a sharp rise in US platform adoption. Strategic partnerships and international expansion efforts underscore the company’s growing footprint in cardiology AI.

Firebrick Pharma is set to expand its Nasodine product line with the launch of a new throat spray, targeting export markets starting November 2025, beginning with Singapore.